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major cause of the inappropriate use of drugs resulting in serious personal injury and related costs
to the health care system. The deﬁnition of useful scientiﬁcally accurate patient information for pre-
scription drugs was accepted by the US Secretary of the Department of Health and Human Services
in 1996 as that derived from or consistent with the US FDA approved professional product label for
a drug. Previous quality content studies found that English language patient drug information leaf-
lets distributed by US pharmacies failed to meet minimum criteria deﬁning useful and scientiﬁcally
accurate information.
Method and ﬁndings: Evaluation forms containing the explicit elements that deﬁne useful scientif-
ically accurate information for three drugs with known serious adverse drug reactions were created
based on the current US FDA approved professional product labels. The Arabic language patient
drug information leaﬂets for celecoxib, paroxetine, and lamotrigine were obtained locally and eval-
uated using a methodology similar to that used in previous quality content patient drug information
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212 S.R. Sukkari et al.The Arabic leaﬂets failed to meet the deﬁnition of useful scientiﬁcally accurate information. The
celecoxib leaﬂet contained 30% of the required information and the paroxetine and lamotrigine
leaﬂets contained 24% and 20%, respectively.
There are several limitations to this study. The Arabic leaﬂets from only one commercial North
American vendor were evaluated and the evaluation included a limited number of drugs. A larger
study is necessary to be able to generalize these results.
Conclusions: The study results are consistent with those of previous quality content studies of com-
mercially available English patient drug information leaﬂets. The results have important implica-
tions for patients as access to a reliable source of drug information may prevent harm or limit
the suffering from serious adverse drug reactions.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The US Food and Drug Administration (US FDA) has said
that the distribution of accurate, thorough and understandable
information about drugs is necessary to fulﬁll both a patient’s
need and the right to be informed. Regardless of any other ef-
fects of such information, the direct educational beneﬁts are
sufﬁcient to justify a government requirement that such infor-
mation be distributed to patients (Department of Health and
Human Services, 1995).
A recent British Medical Journal editorial commented that
‘‘High quality information is essential for good health, yet many
individuals, practitioners, and health organizations – particu-
larly in low and middle income countries – lack information’’
and that the lack of relevant reliable healthcare information
should no longer be a major contributor to avoidable death
and suffering (Smith and Koehlmoos, 2011). This may also in-
clude the lack of useful scientiﬁcally accurate drug information
for patients.
Access by patients to high quality drug information has a
long complex history in the US and is a goal that has not
yet been achieved despite the recognition of its potential bene-
ﬁts and the patients’ right to be informed.
1.1. Patient drug information in the US
In 1979, the US FDA proposed regulations that would have
required the distribution, by pharmacists, of drug information
written speciﬁcally for patients. The information would be in a
nontechnical language; would not be promotional in tone or
content; and would be based on a drug’s approved profes-
sional product labeling (Department of Health and Human
Services, 1979). The regulations were opposed by pharmacy,
medicine, and the pharmaceutical industry (Sasich, 2007).
The day after President Reagan’s inauguration in 1981, the
White House called the US FDA to make it clear that the pa-
tient drug information regulation was not to be enforced. In
1982, US FDA ofﬁcially canceled the regulation in favor of
a plan under which pharmaceutical companies and the private
sector drug information publishers would voluntarily make
information about drugs available to patients (Pines, 1999).
In the 13 years between the ofﬁcial cancellation of the 1979
regulations and 1995 the US FDA proposed new regulations
to ensure that patients received useful scientiﬁcally accurate
drug information called the Medication Guides for all drugs
marketed in the US. During this time the US FDA assessed
the quality of patient information leaﬂets (PILs) produced by
commercial drug information vendors including PILs producedby the American Society of Health-Systems Pharmacists, Facts
and Comparisons, First Data Bank, and the U.S. Pharmaco-
peia. The US FDA found these PILs inadequate. For example,
none of the PILs written for enalapril mentioned the contrain-
dications for allergic reactions or angioedema on previous treat-
ment with other angiotensin converting enzyme inhibitors
(Department of Health and Human Services, 1995).
The US FDA Medication Guide regulations were followed
by the passage of Public Law 104-180 in 1995 that created a
public-private process to develop voluntary guidelines that
would, in part, deﬁne ‘‘useful scientiﬁcally accurate’’ drug
information leaﬂets for patients distributed in pharmacies.
These guidelines are referred to as the Keystone Criteria.
The law required the US FDA to assess the usefulness and sci-
entiﬁc accuracy of private sector PILs. This law prevented the
US FDA from regulating private sectors’ PILs (Department of
Health and Human Services, 1996).
Between 2001 and 2010, four US FDA sponsored evalua-
tions required by Public Law 104-180 assessing the usefulness
and scientiﬁc accuracy of private sector PILs were published.
These evaluations consistently found that private sector PILs
failed to meet the accepted deﬁnition of useful scientiﬁcally
accurate PILs as deﬁned in the Keystone Criteria (Svarstatd
and Mount, 2001; Svarstad et al., 2003a,b; Winterstein et al.,
2010).
Regulations ﬁnalized in 1998 gave the US FDA the author-
ity to required Medication Guides for a limited number of
drugs that were found to present serious public health con-
cerns for which patients should have safety information avail-
able that would help in the decision to begin treatment or
continue taking a drug (Department of Health and Human
Services, 1998). At the present time approximately 200 drugs
are required to be dispensed with a Medication Guide in the
US.
1.2. Patient drug information – international experience
In 2007, Raynor and colleagues evaluated the quality of PILs
provided at the time of dispensing for drugs in the US, UK,
and Australia (Raynor et al., 2003). Legislation passed in the
European Union (EU) that went into effect on January 1,
1999, required that PILs be written and supplied by a drug’s
manufacturer. All contraindications, precautions, and adverse
effects in the Summary of Product Characteristics, the EU
equivalent of the US professional product label, must be in-
cluded in the PIL in a form that the patient can understand.
In Australia the manufacturer is also responsible for writing
the PILs and the content must be consistent with the drugs’
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patient.
According to Raynor and colleagues, the Australian PILs
were generally superior, achieving a level of 90% adherence
to the criteria, compared with 81% for the UK leaﬂets and
68% for those from the US (Raynor et al., 2003).
The original intent of Raynor and colleagues was to evalu-
ate the PILs for four drugs using the US Keystone Criteria in
which the deﬁnition of useful scientiﬁcally accurate informa-
tion is based on consistency with the US FDA approved
professional product label. However, it was found that the
information content for the four drugs from three countries
was different. The authors subsequently modiﬁed the evalua-
tion to accommodate the difference in the information content.
Differences in the information content of professional
product labeling have been identiﬁed between countries,
including between developed and developing countries. The
US Ofﬁce of Technology Assessment (OTA) evaluated a sam-
ple of labeling by the US companies in four developing coun-
tries. Half the products evaluated had labeling that was either
entirely appropriate or had relatively small problems. The
other half differed signiﬁcantly and seriously from the US
FDA approved professional product labels. Health profession-
als relying on the information provided with those products
could put patients at unnecessary risk; provide less-than-
effective treatment, or both. This may occur whenever health
professionals are not fully informed about speciﬁc dangers of
the drugs they are prescribing or recommending, or when they
are led to believe that the drug is effective for a condition when
effectiveness has not been fully established (US Congress Ofﬁce
of Technology Assessment, 1993).
Important differences in safety warnings for rosiglitazone
(Avandia) were found in the prescribing information available
in the UK, US, and Saudi Arabia (SA). In general, more com-
plete information was found in the prescribing information
available in the UK, US compared to SA. The authors noted
that Saudi Arabian prescribers and patients should have access
to the most current safety information to guide their decisions
about the drugs they are taking (Sasich et al., 2009).
The results from the four US FDA sponsored studies and
international experiences prompted our evaluation of the use-
fulness and scientiﬁc accuracy, using the Keystone Criteria def-
inition of Arabic language PILs for three drugs published by a
North American commercial drug information vendor. To the
best of our knowledge this is the ﬁrst evaluation of the useful-
ness and scientiﬁc accuracy of native language PILs, including
Arabic, that has been reported.
2. Methods
We evaluated the usefulness and scientiﬁc accuracy using the
Keystone Criteria for Arabic PILs published by Lexi-Comp,
Inc. a commercial drug information vendor for the drugs
celecoxib, paroxetine, and lamotrigine. The four US FDA
sponsored studies selected two and four drugs for evalua-
tion.(Svarstatd and Mount, 2001; Svarstad et al., 2003a,b;
Winterstein et al., 2010) We choose to evaluate three. The
three drugs were selected because of their potential to cause
serious adverse drug reactions. New prescriptions and reﬁlls
for all three drugs are required in the US to be dispensed with
patient’s Medication Guide.Evaluation forms were developed for each of the three drugs
based on their most recent US FDA approved professional
product labels. The most recent revisions of the professional
product labels for the three drugs were downloaded from the
US National Library of Medicine’s DailyMed website (http://
dailymed.nlm.nih.gov). The celecoxib and paroxetine profes-
sional labels were revised inApril 2011 and the lamotrigine label
in November 2010. Exact statements or phrases concerning
speciﬁc information (explicit elements) were copied from the
electronic versions of the drugs US FDA approved professional
labels. Two columns were created headed Yes or No for the
pharmacist evaluators to indicate whether or not the informa-
tion was contained in the Arabic PILS.
The celecoxib evaluation form contained 37 explicit ele-
ments covering the drug’s box warning; contraindications;
warnings and precautions; drug interactions; use during preg-
nancy and lactation; approved uses; and instructions for pa-
tients on recognizing potential adverse reactions and what
steps to take should such reactions appear. For example, the
statement ‘‘increase risk of serious CV thrombotic events,
MI, and stroke, which can be fatal’’ is an explicit element from
the celecoxib US professional product label that must appear
in the Arabic patient information leaﬂet as part of the evalua-
tion of useful scientiﬁcally accurate information. The evalua-
tion forms for paroxetine and lamotrigine contained 50 and
35 explicit elements, respectively.
The Arabic language PILs for the three drugs were ob-
tained from a large hospital in Doha, Qatar. All of these leaf-
lets had copyright dates of 2011.
The Arabic language PILs were assessed by two experi-
enced bilingual pharmacists, English–Arabic, whose ﬁrst lan-
guage is Arabic using the evaluation forms. The pharmacists
had to agree yes or no for each explicit element in the drug
evaluation forms. An Arabic PIL would have to be 100% con-
sistent with the evaluation form for that drug to be deemed
useful and scientiﬁcally accurate. The proportion of the infor-
mation contained in the Arabic leaﬂets found to be useful and
scientiﬁcally accurate was also calculated.3. Results
In this evaluation of the usefulness and scientiﬁc accuracy of
Arabic language PILs using the US Keystone Criteria as the
standard, the PILs for three drugs with known risks of serious
adverse events failed to meet the deﬁnition of useful and scien-
tiﬁcally accurate drug information for patients.
The Arabic information for celecoxib contained 30% of the
explicit elements deﬁning useful scientiﬁcally accurate informa-
tion. For paroxetine and lamotrigine the results were 24% and
20%, respectively.
The results are summarized in Table 1 below.4. Discussion
The Keystone Guidelines deﬁned useful scientiﬁcally accurate
drug information for patients as that being consistent with
or derived from a drug’s US FDA approved professional prod-
uct label (Department of Health and Human Services, 1995).
The Secretary for Health and Human Services accepted this
deﬁnition in 1996 for drug information distributed to patients
Table 1 Summary results of the evaluation of Arabic patient information leaﬂets.
Celecoxib Paroxetine Lamotrigine
Number of explicit information elements evaluated 37 50 35
Number of explicit information elements meeting keystone criteria 11 12 7
Percentage adherence to the keystone criteria 30% 24% 20%
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ful Prescription Medicine Information, 1996).
Our results assessing the usefulness and scientiﬁc accuracy
of private sector Arabic PILs are consistent with those re-
ported in previous US and international evaluations of English
language PILs. We believe that this is the ﬁrst systematic eval-
uation of the information content of Arabic language drug
information intended for patients.
Overall our assessment found the same result as the US and
international evaluations that none of the three leaﬂets met the
Keystone Criteria guidelines for useful scientiﬁcally accurate
drug information for patients. However, we found lower pro-
portions of explicit information in the Arabic PILs than was
reported for the English language PILs. We believe that this
difference is due to differences in the deﬁnition of useful and
scientiﬁcally accurate drug information and in the scope of
information evaluated.
In our evaluation of the Arabic PILs the original Keystone
Criteria deﬁnition and intent for useful and scientiﬁcally accu-
rate were strictly followed. We restricted our evaluation to the
professional product labeling sections for Indications and
Usage; Black Box Warnings; Contraindications; Drug Interac-
tions; use during pregnancy and lactation; and instructions for
patients on recognizing potential adverse reactions and what
steps to take should such reactions appear. We required that
all information listed in these sections of a drug’s professional
product labeling be reﬂected in the Arabic PILs to be scored as
being useful and scientiﬁcally accurate.
Unlike our evaluation, the Svarstad (Svarstatd and Mount,
2001; Svarstad et al.,2003a,b) and the Winterstein (Winterstein
et al., 2010) studies used standards that did not follow the Key-
stone Criteria strictly. Raynor’s (Raynor et al., 2003) interna-
tional comparison notes that not all information in a drug’s
professional product labeling in Australia needs be in a drug’s
PIL. This may account for the lower scores of the Arabic PILs
found in our study.
We did not evaluate the formatting and readability of the
Arabic language PILs as none of the PILs met the deﬁnition
of useful and scientiﬁc accuracy based on information content.
There is evidence that professional product labeling distrib-
uted by multinational pharmaceutical manufacturers to devel-
oping countries may contain less information than is available
in US FDA approved professional labels (US Congress Ofﬁce
of Technology Assessment, 1993; Sasich et al., 2009). This
raises important questions as to establish a standard to evalu-
ate the usefulness and scientiﬁc accuracy of PILs.
Our use of the Keystone Criteria for deﬁning useful scientif-
ically accurate patient information can be challenged. Other
deﬁnitions are possible that could be developed by professional
organizations in conjunction with patient groups and the
pharmaceutical industry. The Keystone Criteria were chosen
as they were developed by a committee that included groupsrepresenting patients, commercial drug information vendors,
health professionals, and the pharmaceutical industry. Addi-
tionally, the Keystone Criteria were accepted by the US govern-
ment as the standard for patient drug information.
Useful scientiﬁcally accurate drug information may be an
important but overlooked patient safety intervention. The
majority of serious adverse drug reactions are known. A recent
study in the US found that most emergency hospitalizations for
recognized adverse drug reactions in older adults resulted from
a few commonly used medications (Budnitz et al., 2011). Useful
scientiﬁcally accurate drug information may potentially pro-
vide patients the information necessary to avoid or mitigate
known adverse drug reactions. This has important implications
for individual patients and for costs to healthcare systems.
The Arabic language PILs in our study omitted important
risk information. For example, the celecoxib information
made no mention of elderly patients and their increased risks
of adverse cardiovascular events and gastrointestinal hemor-
rhage, both potentially fatal. The paroxetine information in
Arabic omitted the risk of the use of the drug during preg-
nancy, which may result in congenital cardiac abnormalities.
Notable omissions in the lamotrigine Arabic information were
the drug interaction with valproate and the possibility of
potentially fatal multiorgan failure.
Incomplete drug information that omits important warn-
ings is potentially misleading that could result in harm if the
patient believes that drug information distributed with a drug
or by a trusted health professional is all the information that is
necessary to use the drug safely and effectively.
There are several limitations to this study. The patient
information from only one commercial drug information
vendor was evaluated and the evaluation included a limited
number of selected drugs. The two bilingual pharmacists’
assessments were not independent. A larger study is needed
to include additional vendors, drugs, and independent evalua-
tions by bilingual pharmacist assessors.
5. Conclusions
Health professionals and policy makers that are considering
the routine distribution of PILs in their institutions or coun-
tries should consider the failure over the past 30 years of pri-
vate sector commercial drug information vendors to provide
useful accurate drug information for patients. PILs written
by manufacturers and approved by countries with mature drug
regulatory authorities are an option in developed countries.
Developing and emerging countries may not have the re-
sources, including experienced staff, to be able to effectively
regulate native language PILs. Developing and emerging coun-
tries may import drugs from multiple countries with profes-
sional product information that varies in content. A possible
option for developing and emerging countries is to develop
The usefulness and scientiﬁc accuracy of private sector 215their own human resources and the capabilities to write PILs
in their native language using the Keystone Criteria as the
standard for useful scientiﬁcally accurate drug information.
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